Introduction
============

Glaucoma is treated initially with medical therapy or laser procedures. For patients who are unresponsive, surgical treatments may be necessary, and traditionally these include trabeculectomy and tube shunts. If these procedures fail, options to decrease intraocular pressure (IOP) are limited, and either repeat filtering surgery or cyclophotocoagulation can be considered. Common filtering procedures such as trabeculectomy and tube shunts lower IOP by shunting aqueous humor from the anterior chamber of the eye to the sub-conjunctival space. Unlike these methods, the gold shunt exploits an alternate pathway, shunting fluid from the anterior chamber directly into the suprachoroidal space. The gold shunt is a glaucoma drainage implant made of 99.95% gold, measuring 6 mm by 3.5 mm by 0.12 mm, and contains a series of channels to allow for fluid shunting from the anterior chamber. The head of the device is placed in the anterior chamber with the tail placed into the suprachoroidal space. Drainage through this route is possible due to a hydrostatic pressure gradient between these compartments.[@b1-imcrj-9-069],[@b2-imcrj-9-069] The gold shunt has only been approved for use in certain European countries since 2005. Health Canada approved gold shunt use in 2009, and in the United States the gold shunt is currently under Phase III clinical trials. Here, we report a unique case of gold shunt surgery with long-term follow-up in a challenging patient with refractory, advanced, low-tension glaucoma, at risk of losing remaining central vision after multiple failed filtration surgeries previously.

Case report
===========

A 50-year-old male electrical engineer was referred to the glaucoma unit at St. Michael's Hospital on October 20, 2010, for left uncontrolled low-tension glaucoma on maximum medical therapy. His past ocular history included a right eye trabeculectomy, followed by a right Ahmed valve placement and right cataract extraction with lens implantation in 2006. In the left eye, a left Ahmed valve was placed in 2007. A diagnosis of low-tension glaucoma had been previously established by the referring glaucoma specialist. The patient had progressive visual field loss despite IOP in the teens, with multiple failed filtration surgeries. He was highly myopic at −14.00 D in each eye. His family history was negative for glaucoma, and he had a history of remote inhaled steroid use of several months duration. Past medical history included a resolved tuberculosis infection 16 years earlier.

At the time of his visit, he was using brinzolamide 1% tid OU, brimonidine bid OU, timolol 0.5% once am OU, and bimatoprost 0.01% at hs OU. On examination, hand vitiligo was noted. Best corrected visual acuity was 20/30 OD and 20/40 OS and IOPs were 12 mmHg OD and 16 mmHg OS at 12:35 pm. Ocular motility was full, and pupils were equally reactive to light with no afferent pupillary defect. There was marked injection of the inferior lid margins and conjunctiva. Corneal thicknesses were 574 and 576 µm in the right and left eyes, respectively. The right anterior chamber showed a tube entering at the 11 o'clock position and the left anterior chamber showed a tube entering at the 4 o'clock position in the presence of iridotomies superiorly. Angles were wide open, and right posterior chamber intraocular lens was in good position. Early nuclear sclerosis was seen in the left eye. Right optic nerve head revealed severe cupping, and the left optic nerve revealed a 0.8 cup with superonasal neuroretinal rim remaining. Shallow excavation was noted in both eyes. Large temporal zones of beta parapapillary atrophy were also noted. Visual field tests showed right superior hemifield loss splitting fixation and left superior arcuate changes approaching fixation. Left visual field progression over 2 years was documented ([Figure 1A and B](#f1-imcrj-9-069){ref-type="fig"}).

In view of uncontrolled, end-stage, low-tension glaucoma with advanced progressive field loss and IOP in high teens on maximal medical therapy, the options of trabeculectomy with or without cataract extraction and intraocular lens implantation were discussed in detail with the patient. After discussing the benefits and risks of the procedure, the patient elected to proceed with combined left trabeculectomy, cataract extraction, and intraocular lens implantation with mitomycin C. The surgery was performed on November 30, 2010. Several weeks after the surgery, he underwent bleb needling due to rapid scarring and remained uncontrolled despite reinstituting maximal medical therapy. The option of gold shunt surgery was discussed to bypass conjunctival scarring issues, including the benefits and risks, and the patient elected to proceed with gold shunt surgery.

On February 22, 2011, left uncomplicated gold shunt surgery was performed. On the first day after the surgery, best corrected visual acuity was 20/200 OS, IOP measured 6 mmHg OS at 4:20 pm, with trace anterior chamber reaction. He was treated with ofloxacin qid and prednisolone 1% qh for 5 weeks. Left eye visual acuity improved, and IOP remained low over the first 3 months. On July 13, 2011, best corrected visual acuity was 20/20 OD and 20/30+2 OS. Intraocular pressures remained mostly in the low teens, using two glaucoma medications in the right eye only. The gold shunt remained in good position and glaucoma appeared stable ([Figure 2A and B](#f2-imcrj-9-069){ref-type="fig"}). Over a 5-year follow-up period, visual acuity (VA), IOPs, and glaucoma remained stable. On May 27, 2015, best corrected visual acuity was 20/30+2 OD, 20/25−2 OS, and IOP measured 14 mmHg OU at 11:35 am, with no changes in medication. The gold shunt continued to be in good position, and glaucomatous optic neuropathy remained stable ([Figure 3A and B](#f3-imcrj-9-069){ref-type="fig"}). Visual fields remained stable throughout the period of follow-up ([Figure 4A--D](#f4-imcrj-9-069){ref-type="fig"}). At his last visit on October 26, 2015, IOP measured 10 mmHg OU and 12 mmHg OS, with no changes in medication. St. Michael's Hospital Research Ethics Board approval was obtained for this case report, and the patient provided written informed consent.

Discussion
==========

In this challenging case of a young gentleman with low-tension glaucoma, advanced visual field loss, and history of multiple failed glaucoma filtering procedures, the gold shunt effectively reduced IOP without need for glaucoma medications, over 5 years. The efficacy and complication rate between standard surgical interventions, such as trabeculectomy and tube shunts, are similar at 68% and 70%, respectively, at 4 years.[@b3-imcrj-9-069]--[@b5-imcrj-9-069] Glaucoma care is significantly challenged when either of these procedures fail and particularly in patients with good visual potential. In these cases, repeat filtering surgery is typically considered.

In adults with an initial failed procedure, information on the success rate of a second filtration surgery is limited. In pediatric populations, however, repeat procedures of either type after failed trabeculectomy report success rates of 69% and 64% for trabeculectomy and Ahmed valve placement, respectively.[@b6-imcrj-9-069] Cyclophotocoagulation is indicated for patients with refractory glaucoma and limited visual potential due to higher risks of suprachoroid hemorrhage and hypotony.[@b7-imcrj-9-069]--[@b9-imcrj-9-069] Sequential tube shunt success is reported to range from 62% to 75%, similar to cyclophotocoagulation success rates of 66%. Placement of a second tube shunt after primary tube failure has a low reported success rate of 40%.[@b10-imcrj-9-069]

Gold shunt surgery is generally reserved for patients with low visual potential and has success rates ranging from 67% to 79%[@b11-imcrj-9-069],[@b12-imcrj-9-069], comparable to that of Ahmed valves.[@b13-imcrj-9-069] Shunt failure and complications may be due to a variety of factors, including shunt fibrosis possibly from cytokines, varying surgical techniques, and use of older gold shunt models.[@b14-imcrj-9-069]--[@b17-imcrj-9-069] This patient continues to be well controlled 5 years after gold shunt surgery. After previous failed traditional filtration surgeries, the option of gold shunt in the suprachoroidal space may also be considered for patients needing lower IOP in the presence of good central vision.
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![In 2008, Humphrey visual fields show left dense superior field loss with MD of −12.37 dB (**A**) and in 2010, progressive field loss with MD −14.25 dB threatening fixation is noted (**B**).\
**Abbreviation:** MD, mean deviation.](imcrj-9-069Fig1){#f1-imcrj-9-069}

![Four months following surgery, left eye anterior segment shows gold shunt in the superonasal quadrant in good position (**A**), with advanced cupping in a highly myopic left optic nerve (**B**).](imcrj-9-069Fig2){#f2-imcrj-9-069}

![Four years following surgery, left eye anterior segment with gold shunt in good position (**A**), with stable glaucomatous optic neuropathy (**B**).](imcrj-9-069Fig3){#f3-imcrj-9-069}

![Humphrey visual fields show stable left visual fields following gold shunt surgery with MD of −11.84 dB at 1.5 years later (**A**), −12.21 dB at 2.5 years later (**B**), −14.20 dB at 3.5 years later (**C**), and −13.11 dB at 4.5 years later (**D**).\
**Abbreviation:** MD, mean deviation.](imcrj-9-069Fig4){#f4-imcrj-9-069}
